Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06422143 · ClinicalTrials.gov registry record · Phase 3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
A Phase 3 study of Non-Small Cell Lung Cancer and NSCLC, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 851
- Enrollment target
- 20
- Study locations
NCT06422143 is a Phase 3 study of Non-Small Cell Lung Cancer and NSCLC that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 851 participants, above the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (30% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT06422143, a Phase 3 study of Non-Small Cell Lung Cancer and NSCLC, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 851 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of metastatic squamous non-small cell lung cancer. It is hypothesized that pembrolizumab with maintenance sacituzumab tirumotecan is superior to pembrolizumab without sacituzumab tirumotecan maintenance with respect to overall survival (OS).
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Nab-paclitaxel
- BIOLOGICAL sac-TMT
Study Locations (20)
Georgia
- Centricity Research Columbus Cancer Center ( Site 0111) - Columbus
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0001) - Marietta
- Southeastern Regional Medical Center ( Site 0004) - Newnan
Texas
- Memorial Hermann Cancer Center ( Site 0015) - Houston
- Oncology Consultants P.A. ( Site 0124) - Houston
- Mays Cancer Center ( Site 0132) - San Antonio
Colorado
- Exempla Lutheran Medical Center ( Site 0119) - Golden
- Intermountain Health St. Mary's Regional Hospital ( Site 0116) - Grand Junction
New Mexico
- New Mexico Oncology Hematology Consultants Ltd. ( Site 0123) - Albuquerque
- University of New Mexico Comprehensive Cancer Center ( Site 0135) - Albuquerque
Pennsylvania
- St Luke's University Health Network ( Site 0017) - Bethlehem
- Thomas Jefferson University - Clinical Research Institute ( Site 0147) - Philadelphia
Buenos Aires
- Instituto Alexander Fleming ( Site 0203) - Ciudad Autónoma de Buenos Aires
- Instituto de Investigaciones Clínicas Mar del Plata ( Site 0200) - Mar del Plata
Arkansas
- CARTI Cancer Center ( Site 0006) - Little Rock
California
- Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0122) - Burbank
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 851 participants |
| Start Date | 2024-06-10 |
| Est. Completion | 2031-02-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06422143
The ClinicalTrials.gov registry entry for NCT06422143 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 851 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (30% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06422143 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Georgia, Texas, Colorado.
Frequently Asked Questions
What is clinical trial NCT06422143 about?
NCT06422143 is a clinical study titled "Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]". This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of metastatic squamous non-small cell lung cancer. It is hypothesize...
What is the current status of trial NCT06422143?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 851 participants. The study started on 2024-06-10. Estimated completion is 2031-02-12.
What conditions does trial NCT06422143 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, NSCLC.
What interventions are being tested in trial NCT06422143?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Carboplatin (DRUG), Paclitaxel (DRUG), Nab-paclitaxel (DRUG), sac-TMT (BIOLOGICAL).
Who is sponsoring clinical trial NCT06422143?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06422143 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.